Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888

Basit Öğe Kaydı
dc.authorid0000-0002-3052-4556
dc.contributor.authorKaplan, Ozlem
dc.date.accessioned2026-01-24T12:31:00Z
dc.date.available2026-01-24T12:31:00Z
dc.date.issued2023
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractCombination therapy has been frequently preferred in treating various types of cancer in recent years. Targeted cancer therapy has also become one of the remarkable treatment modalities. Therefore, the aim of the study to investigate its cytotoxic and apoptotic effects on liver cancer cell lines by combining the classical chemotherapeutic drug doxorubicin (DOX) and a targeted agent, the new generation HSP90 inhibitor XL-888. The molecular docking method was used to predict the binding conformation of XL-888 on the human Hsp90. The single and combined cytotoxic effects of DOX and XL-888 on liver cancer cell lines HepG2 and HUH-7 were determined by MTT assay. The effect of the combined use of two drugs was evaluated using Chou and Talalay method. The levels of apoptotic genes and heat shock proteins gene and protein expression levels were investigated by quantitative real-time polymerase chain reaction and western blotting, respectively. Molecular docking results showed that XL-888 selectively binds to the ATP binding pocket of HSP90 with an estimated free binding energy of - 7.8 kcal/mol. DOX and XL-888 and their combination showed dose-dependent cytotoxic effect. The combination of drugs showed a synergistic effect on both cell lines. The results revealed that the combination of DOX and XL-888 potently induced apoptosis in liver cancer cell lines rather than using drugs alone. The combined treatment of DOX and XL-888 demonstrated synergistic cytotoxic and apoptotic effects on liver cancer cell lines, presenting a promising approach for combination therapy in liver cancer.
dc.identifier.doi10.1007/s12032-023-02181-9
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue11
dc.identifier.pmid37794195
dc.identifier.scopus2-s2.0-85173789676
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1007/s12032-023-02181-9
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5576
dc.identifier.volume40
dc.identifier.wosWOS:001081600700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHumana Press Inc
dc.relation.ispartofMedical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.subjectHSP90 inhibition
dc.subjectCombination treatment
dc.subjectDoxorubicin
dc.subjectXL-888
dc.subjectLiver cancer
dc.titleSynergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu